Fierce Pharma

BioMarin makes its largest-ever transaction, paying $4.8B for fellow rare disease drugmaker Amicus

In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...

Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types of ...

Hansa Biopharma AB: Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation

The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types ...

Engineered enzyme turns formaldehyde pollutant into key pharmaceutical building block

Formaldehyde is a common chemical used in various industries as a disinfectant, resin precursor, and synthetic intermediate.

A molecular gatekeeper that controls protein synthesis

Researchers at ETH Zurich recently explained the role of a molecular complex that orchestrates the production of proteins in ...

Mitochondria may be missing link between mental health and brain function

A stressful year leads to anxiety. Lasting isolation gives way to depression. An old trauma nags until it becomes paralyzing.

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Amicus Therapeutics (Nasdaq: FOLD) announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an ...

This is the only 2025 best of list you need, and it’s packed with editor picks

Grab a pen and paper and prepare to grow your watch, read, do and listen lists with Reader's Digest's editors' picks for the ...